Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9UIV1
UPID:
CNOT7_HUMAN
Alternative names:
BTG1-binding factor 1; CCR4-associated factor 1; Caf1a
Alternative UPACC:
Q9UIV1; A8MZM5; B3KMP1; B3KN35; D3DSP6; G3V108; Q7Z530
Background:
CCR4-NOT transcription complex subunit 7, known as CCR4-associated factor 1 or Caf1a, exhibits 3'-5' poly(A) exoribonuclease activity, crucial for mRNA degradation and miRNA-mediated repression. It operates within the CCR4-NOT complex, a key cellular mRNA deadenylase linked to transcription regulation and translational repression. Its interaction with BTG family members like TOB1 and BTG2 underscores its role in anti-proliferative activity.
Therapeutic significance:
Understanding the role of CCR4-NOT transcription complex subunit 7 could open doors to potential therapeutic strategies.